focus -WSS

focus

author：hotspot 2025-08-12 09:12:04 - browse：97

Microsoft's head of research Peter Lee speaking at STAT Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

SAN FRANCISCO — Surging interest in generative AI among medical professionals since ChatGPT’s launch is perhaps a testament to its potential — but it could also lead clinicians, and patients to experiment with it before there is wider consensus on how to navigate its biases and other pitfalls, Microsoft’s head of research Peter Lee said Thursday at STAT’s Breakthrough Summit.

About a month after OpenAI — Microsoft has a significant financial stake in the company — launched its chatbot in 2022 on November 30, which happened to be Lee’s birthday, he got a note from a doctor friend who said he’d used it so his receptionist could file after-visit summaries for patients. While Lee and a handful of other doctors at Microsoft had been impressed with the GPT-4’s capabilities, they knew it had weaknesses.

“The emotions were really mixed. I mean we were thrilled,” he said, but then “just within minutes there’s a feeling of dread. We had already come to the realization that GPT-4 would be prone to issues, issues of bias, hallucination, mathematical and logical errors,” he said. “And so, there’s an immediate question: ‘Should we allow this to happen?’”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： 7 more heat

WSS

Hospitals struggle to profit from CAR

Tocagen's brain cancer gene therapy trial continues. Investors worry

Judge rejects Trump's request to move Stormy Daniels hush

Texas Department of Public Safety speaks out on migrant abuse allegations

Indian pharmaceutical industry in denial over drug

Senate committee advances SCOTUS ethics bill after alleged justice misconduct

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

focus

Medicare proposal to cover medical devices draws a mixed reaction

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

FDA approval of Sarepta Duchenne genetic therapy gives me hope

7 more heat

Heart attack and stroke risk calculators need revising

Tesla recalling nearly 16,000 of its 2021

Trump demands the U.S. pay no more for drugs than other countries … again

Argenx drug significantly slows progression of nerve disorder

New air purifier tech could be key to improving indoor air quality

Celiac disease study examines precisely how gluten triggers injury

knowledge

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

Care demand spikes challenge UnitedHealth’s provider arm

J&J expands global access to TB drug amid advocacy campaign

Hospitals struggle to profit from CAR

Argenx drug significantly slows progression of nerve disorder

Congress likely to miss an opportunity to fix drug shortages issue

entertainment

hotspot

knowledge

hotspot